Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Change in Accured Expenses (2020 - 2025)

PROCEPT BioRobotics has reported Change in Accured Expenses over the past 6 years, most recently at $1.8 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $1.8 million for Q4 2025, up 200.66% from a year ago — trailing twelve months through Dec 2025 was $1.9 million (up 1294.03% YoY), and the annual figure for FY2025 was $1.9 million, up 1294.03%.
  • Change in Accured Expenses for Q4 2025 was $1.8 million at PROCEPT BioRobotics, down from $5.3 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for PRCT hit a ceiling of $7.5 million in Q2 2023 and a floor of -$6.0 million in Q1 2023.
  • Median Change in Accured Expenses over the past 5 years was $721000.0 (2021), compared with a mean of $712300.0.
  • Peak annual rise in Change in Accured Expenses hit 568.64% in 2023, while the deepest fall reached 885.15% in 2023.
  • PROCEPT BioRobotics' Change in Accured Expenses stood at $1.0 million in 2021, then soared by 448.64% to $5.7 million in 2022, then plummeted by 44.81% to $3.1 million in 2023, then plummeted by 158.19% to -$1.8 million in 2024, then surged by 200.66% to $1.8 million in 2025.
  • The last three reported values for Change in Accured Expenses were $1.8 million (Q4 2025), $5.3 million (Q3 2025), and -$5.6 million (Q2 2025) per Business Quant data.